Dignitana AB Publishes Q1 2024 Interim Report
Continued progress with increasing activity and awareness
Financial highlights Q1 2024
- Net Sales amounted to 21.2 MSEK (21.5), a decrease of 2 percent over the same quarter in 2023.
- Operating Result amounted to -5.0 MSEK (-3.5).
- Net Result after financial items amounted to -5.1 MSEK (-3.9).
- EBITDA for the First Quarter is negative at -1.1 MSEK (0.2).
- Earnings per share were -0.07 SEK (-0.06).
- Cash Balance amounted at 2.8 MSEK (11.7).
- Average Daily Treatment Revenue (ADTR)* was 241 TSEK (242) in the quarter.
Business highlights during the period
- Dignitana held an Extraordinary General Meeting to resolve on the rights issue and to obtain a bridge loan.
- Dignitana convened Training Academy bringing distributors to Lund Headquarters.
- DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana’s Distribution partner.
- Dignitana signed OncoMedical for distribution in Switzerland and Liechtenstein.
- Preliminary result of DigniCap Delta study in Uruguay demonstrated very high efficacy compared to previous studies.
- DigniCap Delta study is underway in Brindisi, Italy.
- Dignitana nominated for Inaugural Texas Impact Enterprise Awards.
- Dignitana invited to address MedTech innovation on a panel at SXSW® conference in Texas.
Business highlights after the period
- Dignitana Rights Issue was fully subscribed at 19.1 MSEK before issue cost.
- Fredrik Jonsson appointed as CEO beginning 1 May 2024 following resignation of Caterina Lowenadler.
- Dignitana signed an exclusivity agreement with Konica Minolta as distributor for DigniCap in Japan.
- Dignitana exhibited at the Oncology Nursing Congress in Washington, DC
Key Figures
| DIGNITANA GROUP | Q1 2024 | Q1 2023 | Full year 2023 |
| Net sales, TSEK | 21,165 | 21,489 | 86,063 |
| Total revenues, TSEK | 21,288 | 21,605 | 89,025 |
| Net profit after financial items, TSEK | -5,056 | -3,938 | -17,228 |
| Cash and bank balances, TSEK | 2,839 | 11,726 | 6,027 |
| Earnings per share before and after dilution, SEK | -0.07 | -0.06 | -0.25 |
| Average Daily Treatment revenue*, TSEK | 241 | 242 | 239 |
*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2024 08:00 CET.
